BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 33276720)

  • 1. The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do.
    Wang P; Qiao H; Wang R; Hou R; Guo J
    BMC Cardiovasc Disord; 2020 Dec; 20(1):510. PubMed ID: 33276720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of anemia on in-stent restenosis after percutaneous coronary intervention.
    Hu H; Wang S; Tang G; Zhai C; Shen L
    BMC Cardiovasc Disord; 2021 Nov; 21(1):548. PubMed ID: 34798833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study.
    Zhang L; Wang Y; Zhang Z; Liang H; Wu L; Ni L; Gao G; Yang D; Zhao H; Xiao J
    BMC Cardiovasc Disord; 2021 Sep; 21(1):438. PubMed ID: 34525967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visit-to-visit HbA
    Yang CD; Shen Y; Lu L; Yang ZK; Hu J; Zhang RY; Shen WF; Ding FH; Wang XQ
    Cardiovasc Diabetol; 2020 Sep; 19(1):133. PubMed ID: 32887588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.
    Zeng M; Yan X; Wu W
    BMC Cardiovasc Disord; 2021 Sep; 21(1):446. PubMed ID: 34535088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study.
    Qin Z; Zhou K; Li YP; Wang JL; Cheng WJ; Hu CP; Shi C; He H; Zhou YJ
    Cardiovasc Diabetol; 2019 Jan; 18(1):11. PubMed ID: 30691501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis.
    Tocci G; Barbato E; Coluccia R; Modestino A; Pagliaro B; Mastromarino V; Giovannelli F; Berni A; Volpe M
    Am J Hypertens; 2016 Apr; 29(4):509-18. PubMed ID: 26271109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China.
    Li M; Hou J; Gu X; Weng R; Zhong Z; Liu S
    Eur J Med Res; 2022 Jan; 27(1):12. PubMed ID: 35065663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up.
    Cheng G; Chang FJ; Wang Y; You PH; Chen HC; Han WQ; Wang JW; Zhong NE; Min ZQ
    Med Sci Monit; 2019 Jan; 25():240-247. PubMed ID: 30617247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary CT angiography-derived quantitative markers for predicting in-stent restenosis.
    Tesche C; De Cecco CN; Vliegenthart R; Duguay TM; Stubenrauch AC; Rosenberg RD; Varga-Szemes A; Bayer RR; Yang J; Ebersberger U; Baquet M; Jochheim D; Hoffmann E; Steinberg DH; Chiaramida SA; Schoepf UJ
    J Cardiovasc Comput Tomogr; 2016; 10(5):377-83. PubMed ID: 27431607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention.
    He W; Xu C; Wang X; Lei J; Qiu Q; Hu Y; Luo D
    BMC Cardiovasc Disord; 2021 Sep; 21(1):435. PubMed ID: 34521385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Fasting Hypertriglyceridemia as an Independent Risk Factor for Coronary In-Stent Restenosis after Primary Bare Metal Stent Implantation in Patients with Coronary Artery Disease.
    Yoshimura M; Umemoto S; Kawano R; Hiromoto M; Yamada M; Fujimura T; Tanaka M; Nao T; Miura T; Yano M
    Int Heart J; 2021; 62(5):970-979. PubMed ID: 34588411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
    BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents.
    Zhu Y; Liu K; Chen M; Liu Y; Gao A; Hu C; Li H; Zhu H; Han H; Zhang J; Zhao Y
    Cardiovasc Diabetol; 2021 Jul; 20(1):137. PubMed ID: 34238294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
    Zhao LP; Xu WT; Wang L; Li H; Shao CL; Gu HB; Chan SP; Xu HF; Yang XJ
    Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.
    Zbinden R; von Felten S; Wein B; Tueller D; Kurz DJ; Reho I; Galatius S; Alber H; Conen D; Pfisterer M; Kaiser C; Eberli FR
    Cardiovasc Ther; 2017 Feb; 35(1):19-25. PubMed ID: 27662632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.